drugset

drugset / Trial / NCT00301431

Study Evaluating the Efficacy of DVS-233 in Fibromyalgia

NCT00301431 ↗

Phase 2/3 Terminated 1050 enrolled Wyeth is now a wholly owned subsidiary of Pfizer

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine if DVS-233 is safe and effective in the treatment of pain and other symptoms of fibromyalgia syndrome.

Timeline

Start: 2006-08
Primary completion: —
Completion: 2007-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Desvenlafaxine	Other / unclassified	—	—

Indications